# Resveratrol-enriched Grape Extract (Stilvid) in Primary and Secondary Prevention of Cardiovascular Disease

> **NCT01449110** · PHASE2 · COMPLETED · sponsor: **National Research Council, Spain** · enrollment: 150 (actual)

## Conditions studied

- Cardiovascular Diseases

## Interventions

- **DIETARY_SUPPLEMENT:** Placebo in primary cardiovascular prevention (PP)
- **DIETARY_SUPPLEMENT:** Placebo in secondary prevention
- **DIETARY_SUPPLEMENT:** Grape extract in primary prevention (PP)
- **DIETARY_SUPPLEMENT:** Grape extract in SP
- **DIETARY_SUPPLEMENT:** Resveratrol-enriched grape extract in PP
- **DIETARY_SUPPLEMENT:** Resveratrol-enriched grape extract in SP

## Key facts

- **NCT ID:** NCT01449110
- **Lead sponsor:** National Research Council, Spain
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-10
- **Final completion:** 2011-03
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2011-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01449110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01449110, "Resveratrol-enriched Grape Extract (Stilvid) in Primary and Secondary Prevention of Cardiovascular Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01449110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*